Dr. Sperati’s group focuses on complement mediated kidney disorders, glomerular disease, and renal arterial disease secondary to fibromuscular dysplasia. His team has a particular interest in thrombotic microangiopathies involving the complement system.
Dr. Parikh's research focuses on the translation and validation of novel biomarkers for the diagnosis and prognosis of acute kidney injury. Progress in kidney diseases has been hamstrung by significant heterogeneity within the current disease definitions, which are largely based on serum creatinine. Dr. Parikh's research has addressed this critical challenge by developing biomarkers of renal tubular injury, repair, and inflammation to dissect this heterogeneity. He has assembled multicenter longitudinal prospective cohorts for translational research studies across several clinical settings of acute kidney injury and chronic kidney disease for the efficient translation of novel biomarkers.
His research is dedicated to the process of applying discoveries generated in the laboratory and in preclinical experiments, the development of clinical studies, and the design of clinical trials. Dr. Parikh's studies have refined the clinical definition in perioperative acute kidney in...jury and hepatorenal syndrome, developed strategies to reduce kidney discard in deceased donor transplantation, and advanced regulatory approvals of kidney injury biomarkers. He has also developed biomarkers to identify rapid progressors of early diabetic kidney disease before derangements in serum creatinine. Dr. Parikh's research goal is to translate our understanding of pathophysiological mechanisms into clinical practice and improve the outcomes in patients with kidney disease.
Dr. Parikh has also been the recipient of numerous honors, including the 2017 Young Investigator Award from the American Society of Nephrology. view more
Dr. Crews’ team focuses on health disparities in chronic kidney disease. We have studied how social determinants of health, such as poverty and healthful food access, affect disparities in kidney disease outcomes. Our research on end-stage renal disease includes studies of the best timing and environment to initiate dialysis among vulnerable populations.
Dr. Geetha’s team focuses on renal diseases in patients with systemic vasculitis as well as BK virus nephropathy in patients who have undergone renal transplant. Our studies include clinical trials on the effectiveness of rituximab versus cyclosporine in treating idiopathic membranous nephropathy and a multinational study of belimumab with azathioprine for maintaining remission of granulomatosis with polyangiitis and microscopic polyangiitis. We also have conducted research on the treatment of ANCA vasculitis, particularly in kidney transplant patients.
Research in the J. Hunter Young Lab focuses on the genetic epidemiology and physiology of cardiovascular disease and its risk factors, especially hypertension, diabetes and obesity. Current activities include an observational study of hypertension among African Americans; a genetic epidemiology study of worldwide cardiovascular disease susceptibility patterns; and several population-based observational studies of cardiovascular and renal disease. A recent focus group study found that changes in housing and city policies might lead to improved environmental health conditions for public housing residents.
The Pluznick Lab is interested in the role that chemosensation plays in regulating physiological processes, particularly in the kidney and the cardiovascular system.
We have found that sensory receptors (olfactory receptors, taste receptors, and other G-protein coupled receptors) are expressed in the kidney and in blood vessels, and that individual receptors play functional roles in whole-animal physiology.
We are currently working to identify the full complement of sensory receptors found in the kidney, and are working to understand the role that each receptor plays in whole-animal physiology by using a variety of in vitro (receptor localization, ligand screening) and in vivo (whole-animal physiology) techniques.
Work in the Raquel Greer Lab focuses primarily on health disparities in chronic kidney disease. Our most recent research explored the challenges perceived by primary care providers in educating patients about chronic kidney disease as well as physicians’ views on barriers to adequate preparation of patients for renal replacement therapy. We also are interested in examining how clinical-patient communication can impact quality of care in the primary care setting.
Research in the Sharon Turban Lab focuses on the effects of sodium and potassium on blood pressure and on kidney function. We lead the Chronic Kidney Disease-Potassium (CKD-K) clinical trial, funded by American Heart Association, which examines the benefits and safety of two levels of potassium intake in patients with kidney disease. Other research includes the Chronic Renal Insufficiency Cohort (CRIC) study, which aims to improve the understanding of chronic kidney disease and related cardiovascular illness.
Dr. Sozio’s research focuses on 1) Clinical research related to chronic kidney disease and end stage renal disease, and 2) Educational research in undergraduate and graduate medical education.
The Sozio lab pursues work related to stroke, cognitive impairment, manifestations of kidney disease, and systematic reviews on clinical topics, and collaborates on multiple projects with other key investigators. In particular, Dr. Sozio has been an active investigator in the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study, Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) Study, Chronic Renal Insufficiency Cohort (CRIC) Study, and work funded through the Agency for Healthcare Research and Quality (AHRQ) and Johns Hopkins Evidence-Based Practice Center. In addition, the Sozio lab performs studies at the UME and GME levels, investing in understanding learners’ mentorship, research, and transitional experiences.
Research conducted in the Todd Dorman Lab examines the use of informatics in intensive care settings as it relates to remote patient monitoring, safety and management strategies. Specific areas of interest include the surgical stress response; aminoglycoside antibiotics; fungal infections; renal failure; pharmacokinetic models of drug administration; and ICU triage and its impact on disaster preparedness.